Department of Biomedical Engineering , University Medical Center Groningen, University of Groningen , A. Deusinglaan 1, 9713 AV Groningen , The Netherlands.
School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation , Sun Yat-sen University , Guangzhou 510006 , P. R. China.
Acc Chem Res. 2019 Jul 16;52(7):1750-1760. doi: 10.1021/acs.accounts.9b00177. Epub 2019 Jun 25.
Over the past decades, major efforts were undertaken to develop devices on a nanoscale level for the efficient and nontoxic delivery of molecules to tissues and cells, for the purpose of either diagnosis or treatment of disease. The application of such devices in drug delivery has proven to be beneficial for matters as diverse as drug solubility, drug targeting, controlled drug release, and transport of drugs across cellular barriers. Multiple nanotherapeutics have been approved for clinical treatment, and more products are being evaluated in preclinical and clinical trials. However, many biological barriers hinder the medical application of nanocarriers. There are two main classes of barriers that need to be overcome by drug nanocarriers: extracellular and intracellular barriers, both of which may capture and/or destroy therapeutics before they reach their target site. This Account discusses major biological barriers that are confronted by nanotherapeutics, following their systemic administration, focusing on cellular entry and endosomal escape of gene delivery vectors. The use of pH-responsive materials to overcome the endosomal barrier is addressed. Historically, cell biologists have studied the interaction between cells and pathogens in order to unveil the mechanisms of endocytosis and cell signaling. Meanwhile, it is becoming clear that cells may respond in similar ways to artificial drug delivery systems and, consequently, that knowledge on the cellular response against both pathogens and nanoparticulate systems will aid in the design of improved nanomedicine. A close collaboration between bioengineers and cell biologists will promote this development. At the same time, we have come to realize that tools that we use to study fundamental cellular processes, including metabolic inhibitors of endocytosis and overexpression/downregulation of proteins, may cause changes in cellular physiology. This calls for the implementation of refined methods to study nanocarrier-cell interactions, as is discussed in this Account. Finally, recent papers on the dynamics of cargo release from endosomes by means of live cell imaging have significantly advanced our understanding of the transfection process. They have initiated discussion (among others) on the limited number of endosomal escape events in transfection, and on the endosomal stage at which genetic cargo is most efficiently released. Advancements in imaging techniques, including super-resolution microscopy, in concert with techniques to label endogenous proteins and/or label proteins with synthetic fluorophores, will contribute to a more detailed understanding of nanocarrier-cell dynamics, which is imperative for the development of safe and efficient nanomedicine.
在过去的几十年中,人们做出了巨大的努力,旨在开发纳米级别的设备,以便高效、无毒地将分子递送至组织和细胞,从而达到诊断或治疗疾病的目的。此类设备在药物输送中的应用已被证明对于提高药物溶解度、靶向药物、控制药物释放以及药物穿过细胞屏障的运输等方面均具有重要意义。多种纳米药物已被批准用于临床治疗,更多的产品正在进行临床前和临床试验评估。然而,许多生物屏障阻碍了纳米载体在医学上的应用。纳米载体需要克服两类主要的生物屏障:细胞外和细胞内屏障,这两类屏障都可能在纳米载体到达靶位之前捕获和/或破坏药物。本综述讨论了纳米药物在系统给药后所面临的主要生物屏障,重点介绍了基因传递载体的细胞内进入和内涵体逃逸。还讨论了利用 pH 响应材料克服内涵体屏障的问题。历史上,细胞生物学家一直在研究细胞与病原体的相互作用,以揭示胞吞作用和细胞信号转导的机制。同时,人们越来越清楚的是,细胞可能会以类似的方式对人工药物输送系统做出反应,因此,对病原体和纳米颗粒系统的细胞反应的了解将有助于设计改进的纳米医学。生物工程师和细胞生物学家之间的密切合作将促进这一发展。与此同时,我们逐渐意识到,我们用于研究基本细胞过程的工具,包括胞吞作用的代谢抑制剂和蛋白质的过表达/下调,可能会导致细胞生理学发生变化。这就需要实施更精细的方法来研究纳米载体与细胞的相互作用,正如本综述中所讨论的。最后,最近关于通过活细胞成像研究内涵体中货物释放动力学的论文显著提高了我们对转染过程的理解。它们引发了关于转染中内涵体逃逸事件数量有限的讨论,以及关于遗传货物最有效地释放的内涵体阶段的讨论。成像技术的进步,包括超分辨率显微镜,与标记内源性蛋白和/或用合成荧光团标记蛋白的技术相结合,将有助于更详细地了解纳米载体与细胞的动力学,这对于开发安全有效的纳米医学至关重要。